Bismark Dabuo

Mr. Bismark Dabuo

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Advanced Gut & Microbiome Research
Verified
Journal Article
Open access
BDBismark Dabuo
Bismark Dabuo
AAAbudu Abubakari
Abudu Abubakari
FSFrances Ellen Sankah
Frances Ellen Sankah
HAHannah Aryeley Aryee
Hannah Aryeley Aryee
The human microbiota is one of the most powerful sites for antibiotic resistance (AR) genes. It is home to thousands of microbes at various stages of development. The complex inner environment has the potential to affect the host’s immunity, metabolism, and genetic makeup. The gut microbiota has an incredibly high level of gene diversity. Its 3.3 million nonredundant genes even outnumber the host’s 150 million total genomes. In the human gut, where 10–100 trillion diversity‐enhanced microbe cells reside, horizontal gene transfer (HGT) is prevalent and occurs at a rate approximately 25 times higher than in any other ecosystem. AR threatens global health by causing stronger infection rates and higher death tolls. The nonmedical setting that aids in the spread of antimicrobial resistance (AMR) is the human microbiome. Antibiotic resistance genes (ARGs) from commensal, anthropogenic, and environmental microbes make up the antibiotic resistome. The evolutionary force from the use of antibiotics in agriculture and medicine increases AMR. The dynamics of AMR are significantly influenced by the diverse microbial phyla that make up the gut microbiota. Within the human gastrointestinal tract, ARGs are traded and transferred between various bacterial species quite often. This emphasizes how important it is that we understand how the human body functions on the inside as well as the outside sources of infections. ARGs could potentially come from the oral microbiota. Even in the absence of direct selection pressure, genes linked to AR can still be expressed there. The global epidemic of AR claims millions of lives and poses a serious risk to public health and the economy. Bacterial evolution, antibiotic overuse and misuse, genetically modified foods, and the spread of drug‐resistant pathogens through international travel are possibly contributing to AMR. Sustaining AMR requires surveillance, which is hampered by inadequate data collection, knowledge gaps, and low public awareness. In addition to raising death rates, AMR also raises healthcare costs, diminishes treatment effectiveness, and promotes the growth of drug‐resistant bacteria. Without considering agriculture, a knowledge gap, or the proper use of antibiotics, biological factors have contributed significantly to the escalation of AMR. This research summarizes the current knowledge and gaps on antimicrobial‐ and antibiotic‐resistant genes and the contribution of microbiota to AR.

30 November 2022
Verified
Book Chapter
Open access
PDF file
BDBismark Dabuo
Bismark Dabuo
EAEmmanuella Wesome Avogo
Emmanuella Wesome Avogo
GKGabriel Owusu Koomson
Gabriel Owusu Koomson
MAMaxwell Akantibila
Maxwell Akantibila
DGDaniel Ayendo Gbati
Daniel Ayendo Gbati
Aflatoxins, a carcinogenic group of mycotoxins, are naturally occurring toxic fungi that cause illness in both animals and humans. Predominantly found in hot and humid areas, aflatoxins are generated by Aspergillus fungi and are found in a large percentage of the world’s food supply. Aflatoxin B1 (AFB1), being the most potent of the over 18 aflatoxins discovered, is most noted for its role in the development of hepatocellular carcinoma (HCC) in humans and animals, unfortunately, many features of the illnesses it causes and the mechanisms that produce them, remain unexplained. This review examined AFB1 metabolism; its epoxidation and DNA adduction, its correlations to cancer initiation and the mechanisms that underpin it, the synergistic interactions with stunted growth associated with AFB1 intake and kwashiorkor, involvement of oxidative stress and reactive oxygen species. Its harmful effects, including growth retardation, starvation, and immunotoxicity, were also discussed, delving into new findings of AFB1 contamination in worldwide food sources. This review indicated that AFB1 is commonly found in high concentrations in food supplies, notably in maize. To lessen the global burden of AFB1 toxicity, data gathered through this review emphasized the necessity to apply novel and existing techniques to prevent these toxins on other diseases.

11 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
BDBismark Dabuo
Bismark Dabuo
FTFrancis Kwame Morgan Tetteh
Francis Kwame Morgan Tetteh
PCPalanivel Chinnakali
Palanivel Chinnakali
IAIssaka Abubakari
Issaka Abubakari
RORhodalin Naa Yemoteley Odoi
Rhodalin Naa Yemoteley Odoi
EAEmmanuel Parbie Abbeyquaye
Emmanuel Parbie Abbeyquaye
We conducted a cross-sectional study using secondary data from 506 neonates with suspected sepsis to assess improvements in turnaround time, bacterial yield, prescription appropriateness, and death rates during 2022 to 2024 at a tertiary military hospital in Accra, Ghana following operational research for the period 2017- 2020. During, 2022-2024, the median turnaround time, was 48 hours for culture-positive cases and five days for culture-negative cases. 28.9% (n=146) of neonates were discharged before culture results were available, including 27 (5.3%) who were later confirmed culture positive. Overall, 15.4% (n=78) were confirmed culture positive, with late-onset sepsis making up 11.7% (n=59). Treatment was changed in 25.4% (n=128) of post-culture cases, with 4.8% (n=24) were culture positive. Gram-positive organisms were predominant 56.5% (n=39), with coagulase-negative Staphylococcus 37.7% (n=26) and Staphylococcus aureus 13.0% (n=9) being the most common; half of these were multidrug-resistant. Gram-negative also made up 43% (n=30), with Klebsiella pneumoniae as the predominant 20.3% (n=14), followed by E coli 10.1% (n=7). High resistance to penicillin were seen among most isolates with 100% of Enterococcus faecalis, 87.5% of S. aureus, and 66.7% of coagulase-negative Staphylococcus. Turnaround time improved in the present study compared to the previous study, culture positivity decreased to 13.6% in 2022-2024 from 29% during 2017-2020, and mortality rates remained about 7% across both periods. Most frequent empirically prescribed antibiotic combinations include gentamicin (4mg/kg/24-36 hourly) and penicillin (50,000units/kg/12 hourly) 63.6% (n=318), penicillin (50,000units/kg/12 hourly) and amikacin (15mg/kg/24 hourly) 8% (n=40), ciprofloxacin (10mg/kg/12 hourly) and piperacillin-tazobactam ( 90mg/kg/8-12 hourly) 7.8% (n=39), and amikacin (15mg/kg/24 hourly) and piperacillin-tazobactam ( 90mg/kg/8-12 hourly) 7.6% (n=38). 4.8% (n=24) out of the culture-positive reports 15.3% (n=77) treatments were changed, while no readmission was recorded after two weeks post-discharge for those discharges without their report. There was a notable decrease in culture positivity rates and a stable mortality rate from 2017 to 2024; significant challenges remain in the management of neonatal sepsis at this military hospital. Reinforcing infection control measures, strengthening antimicrobial stewardship, and maintaining ongoing resistance surveillance are critical to guiding effective empirical therapy and improving neonatal outcomes in this setting.

7 October 2026 in Discover Public Health
Verified
Journal Article
Open access
PDF file
BDBismark Dabuo
Bismark Dabuo
FTFrancis Kwame Morgan Tetteh
Francis Kwame Morgan Tetteh
PCPalanivel Chinnakali
Palanivel Chinnakali
AIAbubakari Issaka
Abubakari Issaka
RORhodalin Naa Yemoteley Odoi
Rhodalin Naa Yemoteley Odoi
EAEmmanuel Parbie Abbeyquaye
Emmanuel Parbie Abbeyquaye
We conducted a retrospective before and after comparative observational study using routinely collected hospital data from neonates with suspected sepsis a